Wilson Sonsini Goodrich & Rosati is well-known for its niche as a start-up capital markets firm, but it has particular strength in providing such services for life sciences and healthcare sector clients. The firm handles a high volume of fundraising and acquisitions work in the PRC market, both for innovative Chinese companies in the process of growth and foreign companies - such as Australian medical device manufacture Wallaby Medical - aiming to expand their presence and partnerships in China. Dan Ouyang and Can Yin are the key names to note in Beijing. Jie Zhu leads the Shanghai branch of the practice, while Winfield Lau and Weiheng Chen support from Hong Kong.
Key clients
- Citigroup Global Markets
- China International Capital Corporation
Work highlights
- Advised LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. on its USD83.4 million Hong Kong IPO.
- Advised YishengBio Co., Ltd on its USD230 million de-SPAC on Nasdaq.